CiRC Biosciences

CiRC is in pre-clinical development of a potential cell therapy treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Our proprietary technology, chemically induced photoreceptor-like cells (CiPCs) to treat RP, received U.S. FDA Orphan Drug Designation.

We are a portfolio company of Paragon Biosciences.

CiRC Biosciences

CiRC is in pre-clinical development of a potential cell therapy treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Our proprietary technology, chemically induced photoreceptor-like cells (CIPSs) to treat RP, received U.S. FDA Oprhan Drug Designation.

We are a portfolio company of Paragon Biosciences.

CiRC Biosciences

CiRC is in pre-clinical development of a potential cell therapy treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Our proprietary technology, chemically induced photoreceptor-like cells (CiPCs) to treat RP, received U.S. FDA Orphan Drug Designation.

We are a portfolio company of Paragon Biosciences.

Early Symptoms

Early Symptoms

Early Symptoms

There is nothing to show here!
Slider with alias attract-screen-info-slider-mobile-1 not found.